common for women with low-risk tumors, but appeared to be increasing
over time.
For women with high-risk early-stage ovarian cancer, clinical trials
have demonstrated the benefits of adjuvant chemotherapy .
We noted similar results among our cohort of elderlywomenwith ovarian
cancer. Among patients with high-risk, early-stage ovarian cancer,
chemotherapy was associated with improved overall survival. In this
population the survival benefit was modest and limited to overall survival.
Despite the benefits of chemotherapy in this population of